全文获取类型
收费全文 | 51361篇 |
免费 | 4187篇 |
国内免费 | 406篇 |
专业分类
耳鼻咽喉 | 830篇 |
儿科学 | 1094篇 |
妇产科学 | 970篇 |
基础医学 | 8116篇 |
口腔科学 | 810篇 |
临床医学 | 4861篇 |
内科学 | 10360篇 |
皮肤病学 | 1673篇 |
神经病学 | 4429篇 |
特种医学 | 2945篇 |
外科学 | 6021篇 |
综合类 | 542篇 |
现状与发展 | 1篇 |
一般理论 | 16篇 |
预防医学 | 3286篇 |
眼科学 | 1340篇 |
药学 | 4295篇 |
中国医学 | 429篇 |
肿瘤学 | 3936篇 |
出版年
2023年 | 298篇 |
2022年 | 815篇 |
2021年 | 1338篇 |
2020年 | 733篇 |
2019年 | 1139篇 |
2018年 | 1318篇 |
2017年 | 1043篇 |
2016年 | 1519篇 |
2015年 | 1954篇 |
2014年 | 2306篇 |
2013年 | 2740篇 |
2012年 | 3845篇 |
2011年 | 3720篇 |
2010年 | 2315篇 |
2009年 | 1924篇 |
2008年 | 2682篇 |
2007年 | 2665篇 |
2006年 | 2391篇 |
2005年 | 2258篇 |
2004年 | 1930篇 |
2003年 | 1713篇 |
2002年 | 1574篇 |
2001年 | 987篇 |
2000年 | 946篇 |
1999年 | 813篇 |
1998年 | 428篇 |
1997年 | 390篇 |
1996年 | 343篇 |
1995年 | 331篇 |
1994年 | 263篇 |
1993年 | 296篇 |
1992年 | 607篇 |
1991年 | 634篇 |
1990年 | 545篇 |
1989年 | 596篇 |
1988年 | 603篇 |
1987年 | 591篇 |
1986年 | 505篇 |
1985年 | 502篇 |
1984年 | 401篇 |
1983年 | 340篇 |
1982年 | 243篇 |
1981年 | 235篇 |
1980年 | 206篇 |
1979年 | 296篇 |
1978年 | 257篇 |
1977年 | 191篇 |
1974年 | 201篇 |
1973年 | 219篇 |
1972年 | 174篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
993.
994.
Neufeld EJ Galanello R Viprakasit V Aydinok Y Piga A Harmatz P Forni GL Shah FT Grace RF Porter JB Wood JC Peppe J Jones A Rienhoff HY 《Blood》2012,119(14):3263-3268
This was a 24-week, multicenter phase-2 study designed to assess safety, tolerability, and pharmacodynamics of FBS0701, a novel oral chelator, in adults with transfusional iron overload. Fifty-one patients, stratified by transfusional iron intake, were randomized to FBS0701 at either 14.5 or 29 mg/kg/d (16 and 32 mg/kg/d salt form). FBS0701 was generally well tolerated at both doses. Forty-nine patients (96%) completed the study. There were no drug-related serious adverse events. No adverse events (AEs) showed dose-dependency in frequency or severity. Treatment-related nausea, vomiting, abdominal pain, and diarrhea were each noted in < 5% of patients. Mean serum creatinine did not change significantly from Baseline or between dose groups. Transaminases wer increased in 8 (16%), three of whom acquired HCV on-study from a single blood bank while five had an abnormal baseline ALT. The 24 week mean change in liver iron concentration (ΔLIC) at 14.5 mg/kg/d was +3.1 mg/g (dw); 29% achieved a decrease in LIC. Mean ΔLIC at 29 mg/kg/d was -0.3 mg/g (dw); 44% achieved a decrease in LIC (P < .03 for ΔLIC between doses). The safety and tolerability profile at therapeutic doses compare favorably to other oral chelators. 相似文献
995.
Antithymocyte globulin (ATG) + cyclosporine is effective in restoring hematopoiesis in severe aplastic anemia (SAA). We hypothesized that the humanized anti-CD52 mAb alemtuzumab might be active in SAA because of its lymphocytotoxic properties. We investigated alemtuzumab monotherapy from 2003-2010 in treatment-naive, relapsed, and refractory SAA in 3 separate research protocols at the National Institutes of Health. Primary outcome was hematologic response at 6 months. For refractory disease, patients were randomized between rabbit ATG + cyclosporine (n = 27) and alemtuzumab (n = 27); the response rate for alemtuzumab was 37% (95% confidence interval [CI], 18%-57%) and for rabbit ATG 33% (95% CI, 14%-52%; P = .78). The 3-year survival was 83% (95% CI, 68%-99%) for alemtuzumab and 60% (95% CI, 43%-85%) for rabbit ATG (P = .16). For relapsed disease (n = 25), alemtuzumab was administered in a single-arm study; the response rate was 56% (95% CI, 35%-77%) and the 3-year survival was 86% (95% CI, 72%-100%). In treatment-naive patients (n = 16), alemtuzumab was compared with horse and rabbit ATG in a 3-arm randomized study; the response rate was 19% (95% CI 0%-40%), and the alemtuzumab arm was discontinued early. We conclude that alemtuzumab is effective in SAA, but best results are obtained in the relapsed and refractory settings. The present trials were registered at www.clinicaltrials.gov as NCT00195624, NCT00260689, and NCT00065260. 相似文献
996.
Romano E Cotari JW Barreira da Silva R Betts BC Chung DJ Avogadri F Fink MJ St Angelo ET Mehrara B Heller G Münz C Altan-Bonnet G Young JW 《Blood》2012,119(22):5182-5190
997.
Toze CL Dalal CB Nevill TJ Gillan TL Abou Mourad YR Barnett MJ Broady RC Forrest DL Hogge DE Nantel SH Power MM Song KW Sutherland HJ Smith CA Narayanan S Young SS Connors JM Shepherd JD 《British journal of haematology》2012,158(2):174-185
The curative potential of allogeneic haematopoietic stem cell transplant (allo HSCT) in chronic lymphocytic leukaemia CLL is established, with a demonstrated role for graft-versus-leukaemia and less certainty for other factors in determining outcome. The first two decades of CLL patients proceeding to allo HSCT at the Leukaemia/Bone Marrow Transplant Program of British Columbia (n = 49 consecutive, 1991-2009) were studied to clarify factors predicting outcome. The donor was related in 29 (59%) and unrelated in 20 (41%). Conditioning was reduced-intensity in 27 (55%) and myeloablative in 22 (45%). Thirty-one of 49 patients survive with median follow-up of 5 years (0·2-15). Cumulative incidence of non-relapse mortality; complete remission (CR); clearance of fluorescence in situ hybridization (FISH) abnormality and progression at 10 years was 36%; 69%; 55% and 22%. Overall survival (OS) was 63% at 2 years; 55% at 5 years and beyond. Factors predicting OS (P value by log rank <0·05) were: comorbidity index <3, FISH rank (Dohner) and 17p deletion, alemtuzumab pre-HSCT, achievement of CR post-HSCT, donor chimerism >90%, clearance of FISH abnormality post-HSCT and absence of high-grade (3-4) graft-versus-host disease. Results from this province-wide, two-decade cohort demonstrated that a substantial proportion of patients with high-risk CLL become long term disease-free survivors. 相似文献
998.
999.